BS_1TPWFSK6
subependymal giant cell astrocytoma(SEGA)
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- subependymal giant cell astrocytoma(SEGA)
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- subependymal giant cell astrocytoma(SEGA)
- overall_survival_months
- 18.85676741130092
- age_years
- 0.934
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.580
- INTERFERON_GAMMA_RESPONSE+0.571
- TNFA_SIGNALING_VIA_NFKB+0.560
- INTERFERON_ALPHA_RESPONSE+0.540
- IL6_JAK_STAT3_SIGNALING+0.537
- INFLAMMATORY_RESPONSE+0.533
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.516
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.515
- HYPOXIA+0.471
- APOPTOSIS+0.459
Top 10 suppressed
- MYC_TARGETS_V2-0.557
- E2F_TARGETS-0.396
- G2M_CHECKPOINT-0.371
- WNT_BETA_CATENIN_SIGNALING-0.343
- DNA_REPAIR-0.334
- MYC_TARGETS_V1-0.334
- MITOTIC_SPINDLE-0.160
- HEDGEHOG_SIGNALING-0.155
- UNFOLDED_PROTEIN_RESPONSE-0.125
- SPERMATOGENESIS+0.048
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.952 |
| 2 | BS_X16PENSA | pilocytic astrocytoma | — | 0.943 |
| 3 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.933 |
| 4 | sclcM1201764A_S68.txt | — | cohortMD2 | 0.930 |
| 5 | BS_GWCRMKE6 | pilocytic astrocytoma | — | 0.929 |
| 6 | SRR663693 | GTEX | — | 0.929 |
| 7 | BS_HC5M8JTC | low-grade glioma | — | 0.924 |
| 8 | 24d909f2-cdc8-4509-91d5-e18fffcf90eb | — | — | 0.924 |
| 9 | MDT-AP-0385 | Med | Medulloblastoma | 0.919 |
| 10 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.571 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.537 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.533 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.516 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.515 | Inavolisib | — uncovered |
| HYPOXIA | 0.471 | Idelalisib | — uncovered |
| APOPTOSIS | 0.459 | Idelalisib | — uncovered |
| COMPLEMENT | 0.435 | Inavolisib | — uncovered |
| COAGULATION | 0.434 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.433 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.433 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.427 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.414 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.388 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.384 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.374 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.363 | Remibrutinib | — uncovered |